NCT06998407: An ongoing trial by Avenzo Therapeutics, Inc.
This trial is ongoing. It must report results 3 years, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06998407 |
|---|---|
| Title | A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-023 as a Single Agent, and in Combination With AVZO-021 and/or Endocrine Therapy in Patients With Advanced Solid Tumors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 20, 2025 |
| Completion date | Aug. 31, 2028 |
| Required reporting date | Aug. 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |